Durata Therapeutics Meets Primary Endpoints for EMA Review in Phase 3 Clinical Trial

[at noodls] – Download PDF CHICAGO, Jan. 4, 2013 (GLOBE NEWSWIRE) — Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced additional preliminary, top-line results for its DISCOVER 1 (Dalbavancin for Infections … more

View todays social media effects on DRTX

View the latest stocks trending across Twitter. Click to view dashboard

See who Durata is hiring next, click here to view